AIDS biological cell therapeutic instrument

Abstract

The invention provides an AIDS biological cell therapeutic instrument in the field of medicine. The AIDS biological cell therapeutic instrument is characterized in that blood and plasma separators capable of separating plasma, single blood cell and multinucleated giant cells formed by the lodging of HIV is prepared, a hybridoma cell strain both keeping the phagocytic characteristics and performing infinite growth is prepared, the hybridoma cell strain is wrapped with a high polymer material to prepare a purifier after being amplified, then agarose having a gradient concentration is added to fix the hybridoma cell strain to swallow HIV, the purifier constitutes a critical extracorporeal circulation device with the separators together, when the blood flows by the blood separator, the multinucleated giant cells containing the HIV are filtered, when the plasma separated by the plasma separator flows by the purifier, the HIV therein is cleared by the cleaning agent, the purified plasma is conveyed back in vivo after being combined with a single blood cell separated by the plasma separator, and thus the purification treatment purpose of clearing the HIV inside and outside the blood cells is realized.

Description

technical field [0001] The invention relates to the preparation and application of an AIDS biological cell therapy instrument in the medical field, which is mainly used for removing HIV inside and outside blood cells of AIDS patients so as to achieve the purpose of treating AIDS. Background technique [0002] AIDS is an infectious disease caused by human immunodeficiency virus (Human Immunodeficiency Virus, HIV). So far, 208 countries and regions in the world have been seriously threatened by AIDS. About 40 million people have been infected with AIDS, and the death toll has exceeded 20 million. About 6,000 people become AIDS-infected people every day, and more than 300 people die every day. on AIDS. HIV-infected people in China are in a period of rapid growth, and the number has far exceeded 1 million at present. AIDS has become another major infectious disease facing mankind after tumors, cardiovascular and cerebrovascular diseases, tuberculosis, and diabetes, and has bec...

AI Technical Summary

Problems solved by technology

However, the antibody cannot contact the virus remaining in the mononuclear macrophage, and the HIV envelope protein is prone to antigenic variation, and the original antibody loses its effect, so that the neutralizing antibody cannot play its due role

During the latent infection stage, the HIV provirus is integrated into the host cell genome, so HIV will not be recognized by the immune system, so it cannot be eliminated by autoimmunity alone

Another very important reason should be that, based on the mechanism of antibody killing and clearing antigens, it is speculated that after the immune antibody binds to the antigen, if it wants to produce an immune effect, it must either activate the complement and mediate the ADCC effect to dissolve the cellular antigen, but HIV It is not a cellular antigen; either it attracts phagocytes to phagocytize and clear the antigen through chemotaxis, but HIV is protected and proliferates in the phagocytes instead; or the antibody binds to the antigen to neutralize it, making it lose its infectivity, but HIV antigens have many structures Mutations, often making it difficult for antibodies to recognize

[0006] Judging from the current AIDS treatment methods that have been used clinically, the effect is not so ideal: (1) HIV reverse transcriptase inhibitors: can only prevent the infection of susceptible cells that have not been infected with HIV, and have no therapeutic effect on infected cells, and are toxic There are many side effects, including mitochondrial toxicity, myelosuppression, erythrocytic anemia, neutropenia and thrombocytopenia, pancreatitis, and the generation of cross-drug resistance. Drug-resistant variants, resulting in decreased clinical efficacy or failure

(2) HIV protease inhibitors: prone to drug-induced liver injury, lipid metabolism disorders and other side effects and drug resistance

(4) Inhibiting HIV virus entry inhibitors: including blocking the binding of gp120 to CD4, blocking the binding of HIV to coreceptors, acting on gp41 membrane subunits, and acting on CC chemokine receptor 5 (CCR5) on the surface of T lymphocytes to block HIV from entering host cells, but has side effects on the liver and heart

(6) HIV vaccine treatment: Due to the particularity of HIV, such as innate immunity is not enough to resist HIV and its targeted destruction of the immune system, and the virus mutates rapidly, so far no truly safe and effective vaccine has been developed

(7) Gene therapy: HIV gene therapy research has never stopped, including antisense technology, RNA decoy, RNA interference, intracellular antibodies, dominant negative mutants, suicide genes, etc., but gene therapy that has entered phase II clinical trials hardly

[0009] In short, various drugs and biological products cannot effectively kill HIV in the body, and they are expensive and have severe side effects. So far, there is no effective method for the treatment of AIDS, which has become a worldwide problem that cannot be overcome for a long time.

Images